source
- Novo Nordisk halts two cardiovascular trials of inflammation-targeting drug ziltivekimabNovo Nordisk announced it is halting the HERMES and ATHENA cardiovascular trials of its experimental drug ziltivekimab, which was intended to lower inflammation to improve heart health. A data mon…
- ADA panel still reviewing expulsions from June conference, further actions possibleThe American Diabetes Association released top‑line findings on Sept. 1 from an internal panel tasked with reviewing the June 5 expulsion of five members at its New Orleans conference. The full re…